NCT03851731View on ClinicalTrials.gov

Evaluation of Intranasal Naltrexone and Naloxone

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 5, 2015

Primary Completion Date

November 7, 2015

Study Completion Date

November 7, 2015

Conditions
Opioid-use Disorder
Interventions
DRUG

Naltrexone

Intranasal spray

DRUG

Naloxone

Intranasal spray

DRUG

Naltrexol

Intranasal spray

All Listed Sponsors
lead

National Institute on Drug Abuse (NIDA)

NIH

NCT03851731 - Evaluation of Intranasal Naltrexone and Naloxone | Biotech Hunter | Biotech Hunter